

Clinical trials of glyburide

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
glyburide vs c (add on MET)			
DeFronzo , 1995 n=NA follow-up: 29 weeks	metformin and glyburide versus metformin	patients with non-insulin-dependent diabetes mellitus	double-blind USA
Erle , 1999 n=NA follow-up:	low-dose glyburide plus metformin versus high-dose glyburide alone	-	Cross over
glyburide vs control (add on MET)			
Blonde , 2002 n=NA follow-up: 16 weeks	glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg (n = 162) versus metformin 500 mg	patients with inadequate glycaemic control on at least half-maximal dose of sulphonylurea	Parallel groups double-blind
Garber , 2003 n=NA follow-up:	glyburide/metformin versus metformin	patients with type 2 diabetes who had inadequate glycaemic control [glycosylated hemoglobin A(1C) (A1C), >7% and <12%) with diet and exercise alone	Parallel groups
saxagliptin + glyburide vs glyburide uptitration			
CV181-040 [NCT00313313] n=NA follow-up: 24 weeks	saxagliptin added to a submaximal sulphonylurea dose versus uptitration of sulphonylurea monotherapy	patients with type 2 diabetes and inadequate glycaemic control with sulphonylurea monotherapy	
glyburide vs placebo			
Garber , 2002 n=NA follow-up:	glyburide 2.5 mg versus placebo	patients with type 2 diabetes who had failed diet and exercise	Parallel groups double-blind
Vray , 1995 n=NA follow-up:	glibenclamide (2.5 mg X 3/d) versus placebo	type 2 diabetic outpatients, 40-70 years of age, treated by diet alone or oral anti-diabetic drugs	Factorial plan double-blind China

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - sulfonylureas for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q483>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

References

DeFronzo, 1995:

DeFronzo RA, Goodman AM Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9 [7623902] [10.1056/NEJM199508313330902](https://doi.org/10.1056/NEJM199508313330902)

Erle, 1999:

Erle G, Lovise S, Stocchiero C, Lora L, Coppini A, Marchetti P, Merante D A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetol 1999;36:61-5 [10436254]

Blonde, 2002:

Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 2002;4:368-75 [12406033]

Garber, 2003:

Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598-604 [12915642]

CV181-040, :

Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009 Sep;63:1395-406 [19614786]

Chacra AR, Tan GH, Ravichandran S, List J, Chen R Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011;8:150-9 [21562067] [10.1177/1479164111404574](https://doi.org/10.1177/1479164111404574)

Garber, 2002:

Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201-8 [12047399]

Vray, 1995:

Vray M, Attali JR Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes. Diabete Metab 1995;21:433-9 [8593925]

Entry terms: Glyburide, Glybenclamide, Glibenclamide, Diabeta, Euglucon 5, Neogluconin, HB-419, HB 419, HB419, HB-420, HB 420, HB420, Maninil, Micronase, Daonil, Euglucon N, , 4-transhydroxy glyburide, , Glucovance, Glyburide-metformin, , saxagliptin, saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118,